The Efficiency and Pharmacokinetics of DBore-Covidesivir for the Treatment of COVID-19 Virus Infection; Proved as Theoretical and Structural Pattern

An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its caused coronavirus disease 2019 (COVID-19) have been reported in China since December 2019. To date, there are no approved therapeutics or vaccines for covid-19 disease (CVD). Covid-19 is an infectious disease which causes significant morbidity and mortality. Although Covid-19 often causes a simple respiratory infection, it mostly causes disorders affecting several organs including the lungs, headache, brain, muscle pain, shortness of breath (breathing problems), runny nose, fatigue and serious life-threatening primary viral or secondary bacterial pneumonia. Currently, covidesivir is the most important and effective drug for severe. Covidesivir is Chloramphenicol it is used to treat meningitis, plague, cholera and typhoid fever and (+) -artemisinin it is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria derivative synthesized in 2020, is a new antiviral compound. Covidesivir may also assist in decreasing morbidity associated with antimalarial and antiviral infections.